| Ytd | 81.08% | |
| 1y | 207.87% |
| Open | 84.25 | Prev Close | 84.15 | Low | 84.20 | High | 84.34 | Mkt Cap | 8.93B |
| Vol | 947.97K | Avg Vol | 3.75M | EPS | -5.04 | P/E | -16.73 | Forward P/E | -20.65 |
| Beta | 0.12 | Short Ratio | 0.84 | Inst. Own | 122.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 59.74 | 200-d Avg | 47.26 | 1yr Est | 85.50 |
CRNX News
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the
Business Outlook and Conference CallIn light of Crinetics’ July 6, 2026 announcement regarding the p
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.14) per share which beat th
Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billio
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--ACA, CRNX, LEG, an
UBS analyst Ashwani Verma downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Buy to Neutral
Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi
MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde an
BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of V
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billi
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crine
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a lo
It is getting acquired by a larger firm in the sector.
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this we
NEW YORK, July 9, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Asso
The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young
Crinetics Pharmaceuticals (NASDAQ:CRNX) has outperformed the market over the past 5 years by 21.74%
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceutical
Evercore ISI Group analyst Gavin Clark-Gartner downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX)
CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The lates
Market sentiment slightly declines as Nasdaq falls. Crinetics shares soar, Rivian shares dip. Trade
US stocks decline on Tuesday, with Nasdaq falling 0.61% and S&P 500 dropping 0.24%. Consumer sta
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earni
Oppenheimer analyst Leland Gershell downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Outpe
US stocks traded mixed, with the Dow gaining over 200 points as healthcare shares jumped and inform
Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stag
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday&#
Cantor Fitzgerald analyst Josh Schimmer downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from O
HC Wainwright & Co. analyst Douglas Tsao downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) f
Baird analyst Brian Skorney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform a
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vert
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-m
Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the co
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX),
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. Consid
UBS analyst Ashwani Verma initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Bu
HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) w
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies sho
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of
Citizens analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Mark
Evercore ISI Group analyst Maneka Mirchandaney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX)
Analysts changed outlook on top names, RBC raised CC price target, DA Davidson lowered MSA target, O